Form 4: LifeStance Health Group CMO Files for Future Stock Sale

LifeStance Health Group's Chief Medical Officer, Ujjwal Ramtekkar, has filed a Form 4 indicating a planned future sale of 9,519 shares of common stock at a price of $5.17 per share, effective June 16, 2025.

Summary

• Ujjwal Ramtekkar, the Chief Medical Officer of LifeStance Health Group, Inc. (LFST), has filed a Statement of Changes in Beneficial Ownership (Form 4).
• The filing reports a planned disposition (sale) of 9,519 shares of LifeStance Health Group's common stock.
• The transaction date for this planned sale is June 16, 2025.
• The shares are to be sold at a price of $5.17 per share.
• Following this planned transaction, Mr. Ramtekkar will beneficially own 103,916 shares of common stock directly.
• The Form 4 was filed on June 18, 2025.

Sentiment

Score: 4

Explanation: The filing indicates a planned future sale of shares by a key executive. While this could be for personal liquidity or diversification, the pre-announced sale of shares, even if part of a pre-arranged plan, can be perceived as a neutral to slightly negative signal by the market, as it indicates an executive's intent to reduce their stake.

Negatives

• The Chief Medical Officer, Ujjwal Ramtekkar, has reported a planned future sale of 9,519 shares of common stock.
• The planned sale price is $5.17 per share, which represents a reduction in the executive's direct equity stake.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: May interpret the planned insider sale as a signal of an executive's view on the stock's valuation or personal liquidity needs, potentially leading to minor downward pressure or increased scrutiny on the stock.

Key Dates

Recommendation

Keywords

LifeStance Health Group, LFST, Ujjwal Ramtekkar, Chief Medical Officer, Form 4, insider trading, stock sale, equity disposition, healthcare, mental health